Abstract:
A fish feed additive containing fermented soybean by Bacillus polyfermenticus KJS-2 is provided to prevent the infection of parrot fish due to Irido virus by inoculating Bacillus polyfermenticus KJS-2 to beans and fermenting the beans. A fish feed additive contains lactic acid bacteria-fermented soybeans by Bacillus polyfermenticus KJS-2. The fish feed additive shows the prevention effects against Irido virus. The fish feed additive secures a mortality reducing effect. The fish feed additive shows a feed luring effect and a weight gaining effect for cultured fish. The fish feed additive is in a freeze-dry state when in use. The content of fish feed additive is 0.15-15g per kg of feed. The fish feed additive contains 1x10^6~1x10^8cfu of Bacillus polyfermenticus KJS-2 per g of feed.
Abstract:
본 발명은 유해 활성산소(free radical) 소거 효과가 있는 참당귀 추출물의 추출방법에 관한 것이다. 유해 활성산소(free radical) 소거효과가 있는 참당귀 추출물은 그 주성분이 데커신과 데커시놀 안젤레이트가 90% 이상으로 구성된 액체 농축물이며, 본 발명은 참당귀 추출물은 인체에 투여 가능한 형태로 물과 에탄올로만 추출하였고, 또한 고 순도를 위하여 온도와 용해도 차이를 이용한 정제방법을 이용한 것이다. Angelica gigas Nakai, Decursin, Decursinol angelate, antioxidant, free radical
Abstract:
A method of extracting an angelica gigas extract is provided to extracting a high pure material of purity 90% or high by using an ethanol having practicality. A method of an angelica gigas extract is manufactured by extracting Angelica gigas Nakai extraction concentrate as a main component such as decursin, decursinol and decursinol angelate by using an ethanol and water as a solvent and a difference of temperature and solubility. The Angelica gigas Nakai extraction concentrate is manufactured by containing the decursin, the decursinol angelate and the decursinol and removes a free radical.
Abstract:
Novel microorganisms producing DHA(docosahexanoic acid) are provided to supply DHA as an essential nutrient of fishes to fishes through feed additives, and inhibit death of fishes by inhibiting growth of fungi and bacteria, so that income of farmers is enhanced. Novel microorganisms highly producing DHA, Thraustochytrium sp. KJS-1(KCCM 10667P) and Bacillus polyfermenticus KJS-2(KCCM 10769P), are isolated from the sea. The feed additives for cultivating fishes contain freeze-dried, cultivated products of Thraustochytrium sp. KJS-1(KCCM 10667P), Bacillus polyfermenticus KJS-2(KCCM 10769P) and Bacillus licheniformis in a weight ratio of 5:1:2.6. The feed for cultivating fishes contains 1.8% of the feed additives. Further, a bacteria number in culture freezing dried material of the Bacillus polyfermenticus KJS-2 and the Bacillus Licheniformis is 1x10^10 colony per gram.
Abstract:
본 발명은 신규한 바실러스 균주인 바실러스 폴리퍼멘티쿠스 KJS-2( Bacillus
polyfermenticus KJS-2)(KCCM10769P)에서 생산되는 마크로락틴 에이 (Macrolactin A)의 항균물질로서의 용도에 관한 것이다. 본 발명이 제공하는 바실러스 폴리퍼멘티쿠스 KJS-2 ( Bacillus polyfermenticus KJS-2)에서 생산되는 마크로락틴 에이(Macrolactin A)는 각종 미생물과 진균에 대해 넓은 항균 스펙트럼을 보여주고 있으며, 특히, 다제내성균인 반코마이신 내성 장구균(Vancomycin-resistant enterococci , VRE)및 메치실린 내성 황색포도상구균(Methicillin-resistant Staphylococcus
Aureus , MRSA)을 억제하는데 탁월한 효과가 있음이 확인되었다. 따라서 본 발명은 바실러스 폴리퍼멘티쿠스 KJS-2( Bacillus
polyfermenticus KJS-2)가 생산하는 항균물질 마크로락틴 에이(Macrolactin A)는 반코마이신 내성 장구균(VRE) 및 메치실린 내성 황색포도상구균(MRSA)을 억제하는 뛰어난 항균제제를 제공할 수 있으므로 의약 산업상 매우 유용한 발명이다.
Abstract:
An antibacterial macrolactin A produced from Bacillus polyfermenticus KJS-2 is provided to improve range of antibacterial spectrum against various microorganisms and fungi, especially vancomycin-resistant Enterococci(VRE) and methicillin-resistant Staphylococcus aureus(MRSA). An antibacterial macrolactin A produced from Bacillus polyfermenticus KJS-2(KCCM 10769P) has MIC(minimum inhibitory concentration)>90 of 15.63-31.25 mug/ml and 7.81-31.25 mug/ml against vancomycin-resistant Enterococci(VRE) and methicillin-resistant Staphylococcus aureus(MRSA), respectively, and is isolated by culturing Bacillus polyfermenticus KJS-2(KCCM 10769P) in TSB(tryptone soy broth) agar medium, extracting the cultured medium with ethyl acetate, subjecting the extract to LC(liquid chromatography)/Mass to obtain a fraction showing improved antibacterial activity, and purifying the fraction with preparative silica gel RP-18.
Abstract:
A macrolactin A produced from Bacillus polyfermenticus KJS-2 is provided to inhibit growth of various microorganisms and fungi, especially Helicobacter pylori by increasing antibiotic spectrum range, so that the macrolactin A is useful to treat chronic gastritis, stomach ulcer and recurrent ulcer caused by Helicobacter pylori. An antibacterial composition comprises macrolactin A which is produced by culturing Bacillus polyfermenticus KJS-2(KCCM10769P) and purified by extracting the cultured medium of Bacillus polyfermenticus KJS-2(KCCM10769P) with ethylacetate, wherein the effective concentration of macrolactin A is 20 mug/ml or more.
Abstract translation:通过增加抗生素的光谱范围,提供了由芽孢杆菌KJS-2生产的大量的内含乳素A,以通过增加抗生素的光谱范围来抑制各种微生物和真菌,特别是幽门螺杆菌的生长,从而使大黄乳球菌素A可用于治疗由幽门螺杆菌引起的慢性胃炎,胃溃疡和复发性溃疡 幽门螺旋杆菌。 抗菌组合物包括通过培养多发性芽胞杆菌KJS-2(KCCM10769P)产生并通过用乙酸乙酯萃取芽孢杆菌KJS-2(KCCM10769P)培养的培养基进行纯化,其中有效浓度为约20ug / ml 或者更多。
Abstract:
Novel microorganisms producing DHA(docosahexanoic acid) are provided to improve quality of cultivated fishes by supplying DHA as an essential nutrient of fishes to fishes and inhibiting death of fishes, and clean the cultivation tank by inhibiting growth of fungi. The novel microorganisms producing DHA, Thraustochytrium sp. KJS-1(KCCM 10667P) and Bacillus polyfermenticus KJS-2(KCCM 10769P) are selected from microorganisms producing unsaturated fatty acid, isolated from the South coast region. The feed additives for cultivating fishes contain Thraustochytrium sp. KJS-1(KCCM 10667P) and Bacillus polyfermenticus KJS-2(KCCM 10769P), and Bacillus licheniformis.
Abstract:
PURPOSE: Provided are foods and pharmaceutical compositions containing Angelica gigas extract which are effective for alleviation of nephrotoxicity and diabetic hypertension. CONSTITUTION: The foods and pharmaceutical compositions containing Angelica gigas extract are characterized in that they are prepared by extracting and concentrating decursin and decursinol angelate contained in the Angelica gigas, Nakai to be formulated into an oral administration form such as tablet, capsule, liquid medicine and powdered form.